Oncothyreon Inc (USA)  

(Public, NASDAQ:ONTY)   Watch this stock  
Find more results for Nasdaq:ONTY
1.13
-0.01 (-0.88%)
May 27 - Close
NASDAQ real-time data - Disclaimer
Currency in USD
Range 1.12 - 1.16
52 week 0.90 - 4.69
Open 1.14
Vol / Avg. 420,711.00/882,125.00
Mkt cap 104.56M
P/E     -
Div/yield     -
EPS -0.39
Shares 94.96M
Beta 1.76
Inst. own 61%
Aug 4, 2016
Q2 2016 Oncothyreon Inc Earnings Release (Estimated) Add to calendar
May 9, 2016
Q1 2016 Oncothyreon Inc Earnings Release
Mar 14, 2016
Q4 2015 Oncothyreon Inc Earnings Release
Mar 8, 2016
Oncothyreon Inc at Cowen Health Care Conference
More events from DailyFinance »    

Key stats and ratios

Q1 (Mar '16) 2015
Net profit margin - -
Operating margin - -
EBITD margin - -
Return on average assets -56.27% -32.63%
Return on average equity -65.64% -37.24%
Employees 53 -
CDP Score - -

Address

2601 4th Ave Ste 500
SEATTLE, WA 98121-3222
United States - Map
+1-206-8012100 (Phone)
+1-206-8012101 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money

Description

Oncothyreon Inc. (Oncothyreon) is a clinical-stage biopharmaceutical company. The Company focuses on the development of therapeutic products for the treatment of cancer. The Company's clinical-stage product candidate includes ONT-380, an orally active and selective small-molecule human epidermal growth factor receptor (HER) 2 inhibitor. The Company's ONT-10 is a therapeutic vaccine targeting the Mucin 1 peptide antigen (MUC1). The Company is engaged in developing preclinical product candidates in oncology using its Checkpoint kinase 1 (Chk1) kinase inhibitor and protocell technology. The Company completed the evaluation of approximately two dosing cohorts in its Phase Ib trial of ONT-10 in combination with the anti-CD27 T-cell agonist antibody varlilumab in collaboration with other company. The Company has completed Phase I trial of ONT-380 with both dose-escalation and expansion components. The Company has initiated Phase Ib trials of ONT-380.

Officers and directors

Christopher S. Henney Ph.D. Chairman of the Board
Age: 74
Bio & Compensation  - Reuters
Scott D. Myers President, Chief Executive Officer, Director
Age: 50
Bio & Compensation  - Reuters
Julia Marie Eastland Chief Financial Officer, Vice President - Corporate Development, Secretary
Age: 49
Bio & Compensation  - Reuters
Gary W. Christianson Chief Operating Officer
Age: 60
Bio & Compensation  - Reuters
Jay Venkatesan M.D. Executive Vice President, General Manager
Age: 45
Bio & Compensation  - Reuters
Scott Peterson Ph.D. Chief Scientific Officer
Age: 53
Bio & Compensation  - Reuters
Gwendolyn A. Fyfe M.D. Director
Age: 63
Bio & Compensation  - Reuters
Mark Lampert Director
Bio & Compensation  - Reuters
Richard L. Jackson Ph.D. Independent Director
Age: 75
Bio & Compensation  - Reuters
Steven P. James Independent Director
Age: 57
Bio & Compensation  - Reuters